Identifying blood biomarkers for mood disorders using convergent functional genomics

Helen Le-Niculescu, S. M. Kurian, N. Yehyawi, C. Dike, S. D. Patel, Howard Edenberg, M. T. Tsuang, D. R. Salomon, John Nurnberger, Alexander Niculescu

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

There are to date no objective clinical laboratory blood tests for mood disorders. The current reliance on patient self-report of symptom severity and on the clinicians' impression is a rate-limiting step in effective treatment and new drug development. We propose, and provide proof of principle for, an approach to help identify blood biomarkers for mood state. We measured whole-genome gene expression differences in blood samples from subjects with bipolar disorder that had low mood vs those that had high mood at the time of the blood draw, and separately, changes in gene expression in brain and blood of a mouse pharmacogenomic model. We then integrated our human blood gene expression data with animal model gene expression data, human genetic linkage/association data and human postmortem brain data, an approach called convergent functional genomics, as a Bayesian strategy for cross-validating and prioritizing findings. Topping our list of candidate blood biomarker genes we have five genes involved in myelination (Mbp, Edg2, Mag, Pmp22 and Ugt8), and six genes involved in growth factor signaling (Fgfr1, Fzd3, Erbb3, Igfbp4, Igfbp6 and Ptprm). All of these genes have prior evidence of differential expression in human postmortem brains from mood disorder subjects. A predictive score developed based on a panel of 10 top candidate biomarkers (five for high mood and five for low mood) shows sensitivity and specificity for high mood and low mood states, in two independent cohorts. Our studies suggest that blood biomarkers may offer an unexpectedly informative window into brain functioning and disease state.

Original languageEnglish
Pages (from-to)156-174
Number of pages19
JournalMolecular Psychiatry
Volume14
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

Genomics
Mood Disorders
Biomarkers
Gene Expression
Brain Diseases
Genes
Genetic Linkage
Pharmacogenetics
Medical Genetics
Brain
Hematologic Tests
Bipolar Disorder
Self Report
Intercellular Signaling Peptides and Proteins
Animal Models
Genome
Sensitivity and Specificity
Pharmaceutical Preparations

Keywords

  • Biomarkers
  • Bipolar
  • Blood
  • Brain
  • Convergent functional genomics
  • Mood

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Identifying blood biomarkers for mood disorders using convergent functional genomics. / Le-Niculescu, Helen; Kurian, S. M.; Yehyawi, N.; Dike, C.; Patel, S. D.; Edenberg, Howard; Tsuang, M. T.; Salomon, D. R.; Nurnberger, John; Niculescu, Alexander.

In: Molecular Psychiatry, Vol. 14, No. 2, 02.2009, p. 156-174.

Research output: Contribution to journalArticle

Le-Niculescu, Helen ; Kurian, S. M. ; Yehyawi, N. ; Dike, C. ; Patel, S. D. ; Edenberg, Howard ; Tsuang, M. T. ; Salomon, D. R. ; Nurnberger, John ; Niculescu, Alexander. / Identifying blood biomarkers for mood disorders using convergent functional genomics. In: Molecular Psychiatry. 2009 ; Vol. 14, No. 2. pp. 156-174.
@article{0870ad721d98495b87a0f03607a56162,
title = "Identifying blood biomarkers for mood disorders using convergent functional genomics",
abstract = "There are to date no objective clinical laboratory blood tests for mood disorders. The current reliance on patient self-report of symptom severity and on the clinicians' impression is a rate-limiting step in effective treatment and new drug development. We propose, and provide proof of principle for, an approach to help identify blood biomarkers for mood state. We measured whole-genome gene expression differences in blood samples from subjects with bipolar disorder that had low mood vs those that had high mood at the time of the blood draw, and separately, changes in gene expression in brain and blood of a mouse pharmacogenomic model. We then integrated our human blood gene expression data with animal model gene expression data, human genetic linkage/association data and human postmortem brain data, an approach called convergent functional genomics, as a Bayesian strategy for cross-validating and prioritizing findings. Topping our list of candidate blood biomarker genes we have five genes involved in myelination (Mbp, Edg2, Mag, Pmp22 and Ugt8), and six genes involved in growth factor signaling (Fgfr1, Fzd3, Erbb3, Igfbp4, Igfbp6 and Ptprm). All of these genes have prior evidence of differential expression in human postmortem brains from mood disorder subjects. A predictive score developed based on a panel of 10 top candidate biomarkers (five for high mood and five for low mood) shows sensitivity and specificity for high mood and low mood states, in two independent cohorts. Our studies suggest that blood biomarkers may offer an unexpectedly informative window into brain functioning and disease state.",
keywords = "Biomarkers, Bipolar, Blood, Brain, Convergent functional genomics, Mood",
author = "Helen Le-Niculescu and Kurian, {S. M.} and N. Yehyawi and C. Dike and Patel, {S. D.} and Howard Edenberg and Tsuang, {M. T.} and Salomon, {D. R.} and John Nurnberger and Alexander Niculescu",
year = "2009",
month = "2",
doi = "10.1038/mp.2008.11",
language = "English",
volume = "14",
pages = "156--174",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Identifying blood biomarkers for mood disorders using convergent functional genomics

AU - Le-Niculescu, Helen

AU - Kurian, S. M.

AU - Yehyawi, N.

AU - Dike, C.

AU - Patel, S. D.

AU - Edenberg, Howard

AU - Tsuang, M. T.

AU - Salomon, D. R.

AU - Nurnberger, John

AU - Niculescu, Alexander

PY - 2009/2

Y1 - 2009/2

N2 - There are to date no objective clinical laboratory blood tests for mood disorders. The current reliance on patient self-report of symptom severity and on the clinicians' impression is a rate-limiting step in effective treatment and new drug development. We propose, and provide proof of principle for, an approach to help identify blood biomarkers for mood state. We measured whole-genome gene expression differences in blood samples from subjects with bipolar disorder that had low mood vs those that had high mood at the time of the blood draw, and separately, changes in gene expression in brain and blood of a mouse pharmacogenomic model. We then integrated our human blood gene expression data with animal model gene expression data, human genetic linkage/association data and human postmortem brain data, an approach called convergent functional genomics, as a Bayesian strategy for cross-validating and prioritizing findings. Topping our list of candidate blood biomarker genes we have five genes involved in myelination (Mbp, Edg2, Mag, Pmp22 and Ugt8), and six genes involved in growth factor signaling (Fgfr1, Fzd3, Erbb3, Igfbp4, Igfbp6 and Ptprm). All of these genes have prior evidence of differential expression in human postmortem brains from mood disorder subjects. A predictive score developed based on a panel of 10 top candidate biomarkers (five for high mood and five for low mood) shows sensitivity and specificity for high mood and low mood states, in two independent cohorts. Our studies suggest that blood biomarkers may offer an unexpectedly informative window into brain functioning and disease state.

AB - There are to date no objective clinical laboratory blood tests for mood disorders. The current reliance on patient self-report of symptom severity and on the clinicians' impression is a rate-limiting step in effective treatment and new drug development. We propose, and provide proof of principle for, an approach to help identify blood biomarkers for mood state. We measured whole-genome gene expression differences in blood samples from subjects with bipolar disorder that had low mood vs those that had high mood at the time of the blood draw, and separately, changes in gene expression in brain and blood of a mouse pharmacogenomic model. We then integrated our human blood gene expression data with animal model gene expression data, human genetic linkage/association data and human postmortem brain data, an approach called convergent functional genomics, as a Bayesian strategy for cross-validating and prioritizing findings. Topping our list of candidate blood biomarker genes we have five genes involved in myelination (Mbp, Edg2, Mag, Pmp22 and Ugt8), and six genes involved in growth factor signaling (Fgfr1, Fzd3, Erbb3, Igfbp4, Igfbp6 and Ptprm). All of these genes have prior evidence of differential expression in human postmortem brains from mood disorder subjects. A predictive score developed based on a panel of 10 top candidate biomarkers (five for high mood and five for low mood) shows sensitivity and specificity for high mood and low mood states, in two independent cohorts. Our studies suggest that blood biomarkers may offer an unexpectedly informative window into brain functioning and disease state.

KW - Biomarkers

KW - Bipolar

KW - Blood

KW - Brain

KW - Convergent functional genomics

KW - Mood

UR - http://www.scopus.com/inward/record.url?scp=58549118937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58549118937&partnerID=8YFLogxK

U2 - 10.1038/mp.2008.11

DO - 10.1038/mp.2008.11

M3 - Article

VL - 14

SP - 156

EP - 174

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 2

ER -